May Hill Capital LLC Raises Stock Holdings in Boston Scientific Corporation $BSX

May Hill Capital LLC increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 99.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,576 shares of the medical equipment provider’s stock after purchasing an additional 36,143 shares during the quarter. Boston Scientific makes up 0.9% of May Hill Capital LLC’s holdings, making the stock its 21st largest position. May Hill Capital LLC’s holdings in Boston Scientific were worth $6,920,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after buying an additional 1,115,337 shares during the last quarter. Rathbones Group PLC raised its stake in Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after buying an additional 477,680 shares during the last quarter. Tounjian Advisory Partners LLC purchased a new stake in Boston Scientific in the fourth quarter valued at about $1,477,000. Kepler Cheuvreux Suisse SA purchased a new stake in Boston Scientific in the third quarter valued at about $26,955,000. Finally, Waycross Partners LLC purchased a new stake in Boston Scientific in the fourth quarter valued at about $2,384,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 1.7%

Shares of BSX stock opened at $52.67 on Friday. The stock’s 50-day simple moving average is $63.40 and its 200-day simple moving average is $81.79. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm has a market capitalization of $78.27 billion, a PE ratio of 22.04, a P/E/G ratio of 0.97 and a beta of 0.62. Boston Scientific Corporation has a fifty-two week low of $52.52 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. The Goldman Sachs Group decreased their price target on Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Evercore decreased their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Robert W. Baird decreased their price target on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a research note on Thursday, April 23rd. Barclays decreased their price target on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research note on Thursday, April 23rd. Finally, National Bank Financial set a $115.00 price target on Boston Scientific in a research note on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $93.91.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.